Evidence map›Paper›PMID 39122662›Full record

ArticleThe Journal of infectious diseases2025

Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023.

Carla L DeSisto, Rachel L Winer, Troy D Querec, Damilola Dada, Preeti Pathela, Lenore Asbel, John Lin, Jennifer Tang, Alfred Iqbal, Elissa Meites and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carla L DeSistoDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-9065-7070
Rachel L WinerDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Troy D QuerecDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Damilola DadaDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Preeti PathelaBureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, New York City, New York, USA.
Lenore AsbelDivision of Disease Control, Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA.
John LinDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Jennifer TangBureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, New York City, New York, USA.
Alfred IqbalPublic Health Laboratory, Prevention Division, Seattle and King County Department of Public Health, Seattle, Washington, USA.
Elissa MeitesDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Elizabeth R UngerDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lauri E MarkowitzDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

CDC HHS CK14-140105PPHF18Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundWe assessed human papillomavirus (HPV) vaccine effectiveness (VE) against anal HPV among men who have sex with men (MSM) in 2018-2023.

methodsResidual anal specimens from MSM without HIV aged 18-45 years were tested for HPV. We calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for associations between vaccination (≥1 dose) and quadrivalent vaccine (4vHPV)-type prevalence adjusting for city, race/ethnicity, and nonvaccine-type HPV prevalence, stratified by age group (18-26, 27-45 years). VE was calculated as (1 - aPR) × 100.

resultsAmong 2802 persons aged 18-26, 4vHPV-type prevalence was lower in those vaccinated at age <18 (aPR = 0.13; 95% CI, .08-.22; VE = 87%) and those vaccinated ≥2 years before specimen collection (aPR = 0.52; 95% CI, .42-.64; VE = 48%) compared with unvaccinated persons. Among 3548 persons aged 27-45, 4vHPV-type prevalence was lower in those vaccinated at ages 18-26 (aPR = 0.68; 95% CI, .57-.82; VE = 32%) and those vaccinated ≥2 years before specimen collection (aPR = 0.66; 95% CI, .57-.77; VE = 33%) compared with unvaccinated persons. While we observed no VE in persons vaccinated at age >26 overall, 4vHPV-type prevalence was lower in the subgroup vaccinated ≥2 years before specimen collection (aPR = 0.71; 95% CI, .56-.89; VE = 29%).

conclusionsWe found high VE against anal 4vHPV-type prevalence among MSM aged 18-26 who were vaccinated at age <18. Lower VE was observed among MSM aged 27-45 who were vaccinated at age 18-26 or ≥2 years before specimen collection. While ideally vaccination should be given at younger ages, vaccination can prevent some future infections in this population.

Indexed as

Anal CanalHomosexuality, MalePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesVaccine EfficacyAdolescentAdultCitiesHumansMaleMiddle AgedPrevalenceUnited StatesVaccinationYoung AdultPapillomavirus Vaccineshuman papillomaviruspapillomavirus infectionspapillomavirus vaccinessexual and gender minoritiesvaccination

Identifiers

PMID39122662
PMCPMC11878371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.